//

Bayer AG

Posted Mon, 09/14/2009 - 12:20 by Zefu

Bayer AG

51368 Leverkusen, Building W 1
Bayerwerk,
Germany
Phone: (800) 269-2377
Fax: (212) 571-3050
Web Site: http://www.bayer.com/

A. Company Profile

Bayer (NYSE: BAY) is one of world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Bayer.

B. Products

Product Pipelines
Product Indication Clinical Status
BAY43-9006 Liver cancer, melanoma, and advanced kidney cancer Phase II/III

1. BAY43-9006

BAY 43-9006 is an orally active, small molecule agent. It targets the RAF kinase (an enzyme that acts as a control switch for the RAF gene, which helps control tumor growth), receptors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor. This novel compound inhibits both tumor cell proliferation and angiogenesis. BAY43-9006 is being codeveloped by Bayer and Onyx.

2. BAY57-9352

VEGF receptor-2 tyrosine kinase inhibitor.

3. BAY59-8862

BAY59-8862, a novel taxane, exhibits excellent activity against a variety of drug-sensitive and drug-resistant human tumor.